Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study.
Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJ, Locatelli F, Noellke P, Polychronopoulou S, Ravindranath Y, Razzouk B, Reinhardt D, Savva NN, Stark B, Suciu S, Tsukimoto I, Webb DK, Wojcik D, Woods WG, Zimmermann M, Niemeyer CM, Raimondi SC. Hasle H, et al. Among authors: tsukimoto i. Blood. 2007 Jun 1;109(11):4641-7. doi: 10.1182/blood-2006-10-051342. Epub 2007 Feb 13. Blood. 2007. PMID: 17299091 Free article.
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
Kawasaki H, Isoyama K, Eguchi M, Hibi S, Kinukawa N, Kosaka Y, Oda T, Oda M, Nishimura S, Imaizumi M, Okamura T, Hongo T, Okawa H, Mizutani S, Hayashi Y, Tsukimoto I, Kamada N, Ishii E. Kawasaki H, et al. Among authors: tsukimoto i. Blood. 2001 Dec 15;98(13):3589-94. doi: 10.1182/blood.v98.13.3589. Blood. 2001. PMID: 11739161 Free article. Clinical Trial.
Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children.
Kojima S, Ohara A, Tsuchida M, Kudoh T, Hanada R, Okimoto Y, Kaneko T, Takano T, Ikuta K, Tsukimoto I; Japan Childhood Aplastic Anemia Study Group. Kojima S, et al. Among authors: tsukimoto i. Blood. 2002 Aug 1;100(3):786-90. doi: 10.1182/blood.v100.3.786. Blood. 2002. PMID: 12130487 Free article. Clinical Trial.
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.
Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y. Shimada A, et al. Among authors: tsukimoto i. Blood. 2006 Mar 1;107(5):1806-9. doi: 10.1182/blood-2005-08-3408. Epub 2005 Nov 15. Blood. 2006. PMID: 16291592 Free article.
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group. Tomizawa D, et al. Among authors: tsukimoto i. Pediatr Blood Cancer. 2007 Aug;49(2):127-32. doi: 10.1002/pbc.20944. Pediatr Blood Cancer. 2007. PMID: 16807916 Clinical Trial.
Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia.
Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T, Yabe H, Tsuchida M, Mugishima H, Ohara A, Morimoto A, Otsuka Y, Ohga S, Bessho F, Nakahata T, Tsukimoto I, Kojima S; Japan Childhood Aplastic Anemia Study Group. Kosaka Y, et al. Among authors: tsukimoto i. Blood. 2008 Feb 1;111(3):1054-9. doi: 10.1182/blood-2007-08-099168. Epub 2007 Nov 7. Blood. 2008. PMID: 17989314 Free article. Clinical Trial.
Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group.
Tsukimoto I, Tawa A, Horibe K, Tabuchi K, Kigasawa H, Tsuchida M, Yabe H, Nakayama H, Kudo K, Kobayashi R, Hamamoto K, Imaizumi M, Morimoto A, Tsuchiya S, Hanada R. Tsukimoto I, et al. J Clin Oncol. 2009 Aug 20;27(24):4007-13. doi: 10.1200/JCO.2008.18.7948. Epub 2009 Jul 20. J Clin Oncol. 2009. PMID: 19620491
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome.
Kojima S, Sako M, Kato K, Hosoi G, Sato T, Ohara A, Koike K, Okimoto Y, Nishimura S, Akiyama Y, Yoshikawa T, Ishii E, Okamura J, Yazaki M, Hayashi Y, Eguchi M, Tsukimoto I, Ueda K. Kojima S, et al. Among authors: tsukimoto i. Leukemia. 2000 May;14(5):786-91. doi: 10.1038/sj.leu.2401754. Leukemia. 2000. PMID: 10803507 Clinical Trial.
105 results